TG THERAPEUTICS INC
For the period ended May 1, 2024. Filed May 1, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 1, 2024 · Filed May 1, 2024
Use the contents to explore the available documents and sections.
TGTX$59.83+3.2%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Highlights & Developments
Recent Highlights & Developments
United States (U.S.) Commercialization of BRIUMVI®(ublituximab-xiiy)
| ● | BRIUMVI U.S. net product revenue of $50.5 million for the first quarter of 2024, representing >25% quarter over quarter growth |
| ● | Approximately 4,450 BRIUMVI new patient prescriptions received by the TG Therapeutics hub since launch, including more than 1,250 in the first quarter of 2024, from approximately 800 healthcare providers at approximately 450 centers |
| ● | Awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI to be the preferred agent listed on the VA National Formulary for anti-CD20 antibody indications for patients with relapsing forms of multiple sclerosis |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.